Document Detail

Von Willebrand's disease and angiodysplasia treated with thalidomide.
MedLine Citation:
PMID:  16643215     Owner:  NLM     Status:  MEDLINE    
A 54-year-old man with type IIB VWD and severe angiodysplasia had such a large blood loss from the bowel that it was difficult to keep up with transfusion requirements. Treatment with factor eight concentrate barely slowed the loss. D.D.A.V.P., Octreotide, and recombinant activated Factor VII, tried separately, were ineffective. The use of Thalidomide at a dose of 150 mg daily has rendered him free from blood loss for the last six months and we suggest would be worth a trial in similar cases.
H M Hirri; P J Green; J Lindsay
Related Documents :
6259245 - Fast stopped-flow microcalorimeter.
16999755 - Significant reduction in blood loss in patients undergoing minimal extracorporeal circu...
7138785 - Plasma levels of immunoreactive erythropoietin after acute blood loss in man.
1924565 - The effect of epinephrine on blood loss during suction lipectomy.
8350665 - Endothelin-1-induced gastric ulcer is attenuated by cetraxate.
1852985 - Significance of bulk convection during high-frequency oscillation.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Haemophilia : the official journal of the World Federation of Hemophilia     Volume:  12     ISSN:  1351-8216     ISO Abbreviation:  Haemophilia     Publication Date:  2006 May 
Date Detail:
Created Date:  2006-04-28     Completed Date:  2006-09-29     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  9442916     Medline TA:  Haemophilia     Country:  England    
Other Details:
Languages:  eng     Pagination:  285-6     Citation Subset:  IM    
Portsmouth Hospitals NHS Trust, Portsmouth, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiodysplasia / complications,  drug therapy*
Angiogenesis Inhibitors / therapeutic use*
Middle Aged
Thalidomide / therapeutic use*
Treatment Outcome
von Willebrand Diseases / complications,  drug therapy*
Reg. No./Substance:
0/Angiogenesis Inhibitors; 50-35-1/Thalidomide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Failure of rituximab to induce immune tolerance in a boy with severe haemophilia A and an alloimmune...
Next Document:  Patient injuries in response to anaesthetic procedures: cases evaluated by the Danish Patient Insura...